Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase lb study

@inproceedings{Zakharia2017TargetingEF,
  title={Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase lb study},
  author={Yousef Zakharia and Varun Monga and Umang Swami and Aaron D. Bossler and Michele Freesmeier and Melanie Frees and M. Shakir Khan and Noah Frydenlund and Rithu Srikantha and Marion Vanneste and M. David Henry and Mohammed Milhem},
  booktitle={Oncotarget},
  year={2017}
}
Introduction Epigenetic modifications play an important role in progression and development of resistance in V600EBRAF positive metastatic melanoma. Therefore, we hypothesized that the action of vemurafenib (BRAF inhibitor) can be made more effective by combining with low dose decitabine (a DNA methyltransferase inhibitor). The primary objective of this phase lb study was to determine the dose limiting toxicity and maximum tolerated dose of combination of subcutaneous decitabine with oral… CONTINUE READING